Bayer and LANXESS to sell their stakes in Currenta to Macquarie Infrastructure and Real Assets
Currenta valued with an attractive enterprise value of EUR 3.5 billion (100%) (Source: Bayer Company News)
Source: Bayer Company News - August 6, 2019 Category: Pharmaceuticals Source Type: news
U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancer (for specialized target groups only)
Darolutamide was approved in the U.S. under the FDA Priority Review designation; approval granted three months ahead of target FDA action date / Approval based on Phase III ARAMIS trial evaluating the efficacy and safety of darolutamide plus androgen deprivation therapy (ADT) compared to placebo plus ADT (Source: Bayer Company News)
Source: Bayer Company News - July 31, 2019 Category: Pharmaceuticals Source Type: news
Bayer on track in operational business
Group sales increase by 0.9 percent (Fx& portfolio adj.) to 11.485 billion euros / EBITDA before special items advances by 24.7 percent to 2.927 billion euros / Crop Science sees sales decline (Fx& portfolio adj. and pro forma) in challenging environment but posts substantial earnings growth due to acquired business / Pharmaceuticals posts higher sales and strong earnings growth / Consumer Health increases sales and earnings / Net income falls by 49.1 percent to 404 million euros, held back by special items for restructuring and impairments / Core earnings per share increase by 5.9 percent to 1.62 euros / Group outlook con...
Source: Bayer Company News - July 30, 2019 Category: Pharmaceuticals Source Type: news
Bayer receives positive CHMP opinion for precision oncology treatment larotrectinib with first ever tumor-agnostic indication in in Europe (for specialized target groups only)
Recommendation for approval for the treatment of adults and children with locally advanced or metastatic solid tumors that have a rare genomic alteration called an NTRK gene fusion / Upon approval, larotrectinib would be the first therapy in Europe with a tumor-agnostic indication / CHMP opinion is based on pooled data showing that larotrectinib provides high and durable responses in adult and pediatric patients with TRK fusion cancer, including CNS tumors / Larotrectinib showed a favorable safety profile, with the majority of adverse events being grade 1 or 2 / Final decision from the European Commission is anticipated wi...
Source: Bayer Company News - July 26, 2019 Category: Pharmaceuticals Source Type: news
Yellow Wood Partners to acquire iconic Dr. Scholl & #8217;s & #8482; brand from Bayer
(Source: Bayer Company News)
Source: Bayer Company News - July 22, 2019 Category: Pharmaceuticals Source Type: news
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga ® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with colorectal cancer (for specialized target groups only)
Combination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer / Companies plan indication-seeking trial (Source: Bayer Company News)
Source: Bayer Company News - July 18, 2019 Category: Pharmaceuticals Source Type: news
Rivaroxaban demonstrates strong efficacy and safety profile in phase III study in children with thromboembolism (for specialized target groups only)
Phase III EINSTEIN-Jr. study in children concludes the largest pediatric thromboembolism program delivering results consistent with those in adults / Study shows a low risk of recurrent venous thromboembolism (VTE) in children treated with rivaroxaban compared with standard of care with low rates of bleeding / First phase III data on the use of a non-vitamin K oral anticoagulant (NOAC) in a large pediatric population / Study investigated a body weight-adjusted oral 20 mg equivalent dose of rivaroxaban for the prevention of recurrent VTE in children from birth to 17 years of age with confirmed VTE, including cerebral vein a...
Source: Bayer Company News - July 8, 2019 Category: Pharmaceuticals Source Type: news
Century Therapeutics launches with USD 250M financing for induced pluripotent stem cells (iPSC) allogeneic cell therapy platform
Created by Versant Ventures and partnered with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies / Leaps by Bayer leads investment round with USD 215 million commitment to develop next-generation immune oncology treatments (Source: Bayer Company News)
Source: Bayer Company News - July 1, 2019 Category: Pharmaceuticals Source Type: news
Bayer Supervisory Board takes action to address the glyphosate litigation and welcomes the appointment of Ken Feinberg
as mediator
(Source: Bayer Company News)
Source: Bayer Company News - June 26, 2019 Category: Pharmaceuticals Source Type: news
Bayer initiates Phase III trial of Aflibercept to prevent blindness in premature infants (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - June 21, 2019 Category: Pharmaceuticals Source Type: news
Regorafenib to be tested in brain cancer patients in multi-arm cooperation trial (for specialized target groups only)
GBM AGILE, an international platform trial sponsored by the Global Coalition for Adaptive Research (GCAR) to evaluate multiple therapies for patients with newly diagnosed and recurrent glioblastoma, is now open for enrollment in the US with regorafenib as the first treatment arm / Results from the Phase II REGOMA study (Lombardi G et al, Lancet Oncol, 2018) support further evaluation of regorafenib in patients with newly diagnosed and recurrent glioblastoma, the most aggressive form of brain cancer / Medical need remains high in glioblastoma as treatment options are limited and patient outcomes have remained largely unchan...
Source: Bayer Company News - June 19, 2019 Category: Pharmaceuticals Source Type: news
Bayer raises the bar in transparency, sustainability and engagement
With its solutions, the company aims to reduce environmental impact by 30 percent / Approximately 5 billion euros will be invested in additional methods to combat weeds over the next decade / Invitation to scientists, journalists and NGO representatives to participate in the scientific preparation for the upcoming EU glyphosate re-registration process / Crop protection products will only be sold in developing countries if they meet the standards of a majority of leading regulators on top of local regulations (Source: Bayer Company News)
Source: Bayer Company News - June 14, 2019 Category: Pharmaceuticals Source Type: news
New data on larotrectinib efficacy in patients with TRK fusion cancer and primary CNS tumors or brain metastases presented at ASCO 2019 (for specialized target groups only)
In five TRK fusion cancer patients with brain metastases across different tumor histologies, the overall response rate was 60%, with disease control achieved in all patients / In 14 adult and pediatric patients with TRK fusion cancer with primary central nervous system (CNS) tumors (including high grade gliomas), the overall response rate was 36% including two complete responses / 71% of evaluable patients with primary CNS tumors experienced disease control for 24 weeks or more / First prospective analysis of the activity of larotrectinib in patients with TRK fusion cancer and intracranial disease, including first data eve...
Source: Bayer Company News - June 3, 2019 Category: Pharmaceuticals Source Type: news
New data for larotrectinib show overall response rates of 94% in children and 76% in adults with TRK fusion cancer; clinical benefit demonstrated in patients with primary central nervous system tumors and brain metastases (for specialized target groups only)
In children with TRK fusion cancer (n=34), the overall response rate (ORR) was 94% and durable, with median duration of response (DOR) not reached / In adults with TRK fusion cancer (n=74), the ORR was 76% and durable, with median DOR not reached / In evaluable patients with brain metastases (n=5), ORR was 60% / Improvements in quality of life were shown with larotrectinib treatment in both children and adults / Majority of adverse events were grade 1 or 2, as reported in prior publications (Source: Bayer Company News)
Source: Bayer Company News - May 15, 2019 Category: Pharmaceuticals Source Type: news
